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Abstract 
Chronic Obstructive Pulmonary Disease (COPD) is characterised by reduced lung function and is the 
third leading cause of death globally. Through genome-wide association discovery in 48,943 
individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 
95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A 
genetic risk score was associated with COPD susceptibility (odds ratios per standard deviation of the 
risk score (~6 alleles) (95% confidence interval) 1.24 (1.20-1.27), P=5.05x10-49) and we observed a 3.7 
fold difference in COPD risk between highest and lowest genetic risk score deciles in UK Biobank. The 
97 signals show enrichment in development, elastic fibres and epigenetic regulation pathways. We 
highlight targets for drugs and compounds in development for COPD and asthma (genes in the 
inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug 
repositioning from other clinical indications. 
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Main text  
 
Maximally attained lung function and subsequent lung function decline together determine the risk 
of developing Chronic Obstructive Pulmonary Disease (COPD)1,2. COPD, characterised by irreversible 
airflow obstruction and chronic airway inflammation, is the third leading cause of death globally3. 
Smoking is the primary risk factor for COPD but not all smokers develop COPD and more than 25% of 
COPD cases occur in never-smokers4. Patients with COPD exhibit variable presentation of symptoms 
and pathology, with or without exacerbations, with variable amounts of emphysema and with 
differing rates of progression. Although risk factors for COPD are known, including smoking and 
environmental exposures in early5,6 and later life, the causal mechanisms are not well understood7. 
Disease-modifying treatments for COPD are required7.  
Understanding genetic factors associated with reduced lung function and COPD susceptibility could 
inform drug target identification, risk prediction and stratified prevention or treatment. Previous 
genome-wide association studies (GWAS) of COPD identified several independent COPD-associated 
variants8-10 but the rate and scale of discovery has been limited by available sample sizes. We 
conducted a powerful GWAS for lung function, and followed up the robustly-associated variants in 
COPD case-control studies. Although previous GWAS have reported genome-wide significant 
associations with lung function11-16, there has not been a comprehensive study confirming the effect 
of these variants on COPD susceptibility. In this study, we hypothesised that: (i) undertaking GWAS 
of lung function of unprecedented power and scale would detect novel loci associated with 
quantitative measures of lung function; (ii) collectively these variants would be associated with the 
risk of developing COPD, and (iii) aggregate analyses of all novel and previously-reported signals of 
association, and the identification of genes through which their effects are mediated, would reveal 
further insight into biological mechanisms underlying the associations. Together these findings could 
provide potential novel targets17 for therapeutic intervention and pinpoint existing drugs which 
could be candidates for repositioning18 for the treatment of COPD. 
Results 
43 new signals for lung function 
For stage 1, genome-wide association analyses of forced expired volume in 1 second (FEV1), forced 
vital capacity (FVC) and FEV1/FVC were undertaken in 48,943 individuals from the UK BiLEVE study16 
who were selected from the extremes of the lung function distribution in UK Biobank (total 
n=502,682). From analysis of 27,624,732 variants, 81 independent variants associated with one or 
more traits with P<5x10-7 were selected for follow-up in stage 2, consisting of a further 95,375 
independent individuals from UK Biobank, the SpiroMeta consortium and UK Households 
Longitudinal Study (UKHLS) (Supplementary Table 1). No evidence of sample overlap between stage 
1 and stage 2 studies or between stage 2 studies was identified using LD score regression 
(Supplementary Table 2). Following meta-analysis of stage 1 and stage 2 results, 43 signals showed 
genome-wide significant (P<5x10-8) association with one or more of FEV1, FVC or FEV1/FVC (Table 1, 
Supplementary Table 3 and Supplementary Figure 1). We report these 43 signals as novel 
independent signals (Figure 1), almost doubling the number of confirmed independent genomic 
signals for lung function to 97 (Supplementary Table 4). Of the 43 novel signals, 33 represented 
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novel loci whilst 10 were statistically independent signals (conditional P<5x10-7) within 500kb of 
another association signal. Based on an assumed heritability of 40%19,20 for each lung function trait, 
the novel signals explained 4.3% of the heritability of FEV1, 3.2% for FVC and 5.2% for FEV1/FVC 
bringing the total heritability explained by the 97 signals to 9.6%, 6.4% and 14.3%, respectively. The 
estimated effect sizes of lung function associated variants in children were correlated with those in 
adults (r=0.65, 73 variants with high imputation quality, Supplementary Figure 2). A genetic risk 
score based on these 73 variants, was also significantly associated with FEV1 and FEV1/FVC in 
children, (per risk allele β (s.e.) =  -0.0177 (0.0040), P=1.03x10-5 and per risk allele β (s.e.) = -0.0213 
(0.0037), P=1.27x10-8, respectively), but not with FVC (per risk allele β (s.e.) = -0.0037 (0.0041), 
P=0.366).  
Using the stage 1 results, a 95% ‘credible set’ of variants (i.e. the set of variants that were 95% likely 
to contain the underlying causal variant, based on Bayesian refinement) was defined for all (novel 
and previously reported) association signals for which this was feasible (67 signals, Online Methods 
Supplementary Figures 3, 4 and 5 and Supplementary Table 5); 13 of these signals were fine-
mapped to <=10 plausible causal variants and for 63 of the 67 signals fine-mapped, the sentinel 
(lowest P value) variant was also the top ranked variant by posterior probability. In addition, by 
refining six chromosome 6 MHC region association signals using imputation of classical alleles and 
amino acid changes (Online methods), we identified the MHC class II HLA-DQB1 gene product, HLA-
DQβ1, amino acid change at position 57 (alanine compared to non-alanine) as the main driver of 
signals in the MHC region for both FEV1 (β (s.e.) = 0.048 (0.007), P=5.71×10-13, Supplementary Figure 
6a) and FEV1/FVC (β (s.e.) = 0.062 (0.007), P=1.17×10-20, Supplementary Figure 6c) with secondary 
non-HLA gene signals in the MHC region remaining after conditioning on the HLA-DQβ1 position 57 
variant for rs34864796:G>A (near ZKSCAN3, FEV1; conditional β (s.e.) = -0.058 (0.01), P=1.26x10-9, 
Supplementary Figure 6b) and rs2070600:C>T (in AGER, FEV1/FVC; conditional β (s.e.) = 0.120 
(0.013), P=4.23x10-20, Supplementary Figure 6d), (Supplementary Table 6).  
We identified that 29 of the lung function-associated signals had previously shown genome-wide 
significant association in GWAS of traits other than lung function or COPD. This included associations 
with inflammatory bowel disease (Crohn’s disease and/or ulcerative colitis, 3 signals) and height (9 
signals, 3 of which showed a consistent direction of effect on height and the lung function measure 
with which they were most strongly associated) (Supplementary Table 7). With the exception of 
KANSL116, there was no significant (P<5.15x10-4) association with smoking for any of the signals 
(Supplementary Table 8).  
95 variants and COPD susceptibility 
The disease-relevance of lung function-associated variants has been questioned21. Therefore we 
tested association with COPD susceptibility for variants representing 95 of the 97 lung function 
associated signals in up to 20,086 COPD cases and 215,630 controls (data were unavailable for 
further study for the X-chromosome variant, rs7050036:A>T near AP1S2, and a rare variant, 
chr12:114743533:C>T) (Supplementary Table 9). These cases and controls comprised the COPD 
study at deCODE Genetics22, (COPD cases defined using spirometry, population-based controls 
excluding known cases, up to 1,964 moderate-severe cases, up to 142,262 controls), three lung 
resection cohorts23-25 (COPD definition based on spirometry, 310 moderate-severe cases, 332 
controls), four case-control studies employing post-bronchodilator spirometry8-10,26-29 (5,778 
8 
 
moderate-severe cases, 3,950 controls), two studies within which COPD was determined from 
electronic medical records30 (eMR, total 1,487 cases, 15,138 controls), additional UK Biobank 
samples (COPD definition based on spirometry, 984 moderate-severe31 cases and 26,561 controls) 
and UK BiLEVE (COPD definition based on spirometry, 9,563 moderate-severe cases, 27,387 
controls). UK BiLEVE COPD cases and controls were only used for single variant COPD association 
tests for the subset of 47 variants discovered independently from UK BiLEVE (that is excluding the 43 
variants discovered using the UK BiLEVE data described in this paper and 5 variants reported in our 
previous study in the UK BiLEVE population16). Across all 95 variants, 51 showed nominal COPD 
association (P<0.05) and 30 showed associations with COPD susceptibility reaching a Bonferroni 
corrected threshold for 95 tests (P<5.26x10-4, Supplementary Table 10). Of these 30, 27 were 
variants discovered independently from UK BiLEVE and 3 were from the 48 lower powered 
association tests not including UK BiLEVE cases and controls.  
Using a risk score based on the available 95 sentinel variants or their best proxies, and using data 
from up to 9791 COPD cases and 120,462 controls (Online Methods), for the meta-analysis the OR 
(95% CI) per standard deviation change in risk score (~6 alleles) was 1.24 (1.20-1.27), P=5.05x10-49 
(Figure 2a, Supplementary Table 11). We observed considerable heterogeneity in effect estimates 
between the different COPD studies (I2=92%) which had different approaches to ascertainment of 
COPD cases and variable disease severity. In UK Biobank (including UK BiLEVE) we found broadly 
similar effect size estimates of moderate-severe COPD to those in COPD case-control studies 
employing post-bronchodilator spirometry (OR=1.42 versus 1.36) and therefore we undertook 
further modelling showing a gradation in susceptibility to moderate-severe COPD across deciles of 
allelic risk score (Online Methods). The risk of moderate-severe COPD was more than three times 
higher in the top decile than the bottom decile (OR 3.71, 95% CI 3.33 to 4.12, Figure 2b). The 
estimated proportion of COPD cases attributable to allelic risk scores above the first decile 
(population attributable risk fraction) was 48.0% (95% CI 43.6 to 52.2%).  
We tested association of individual variants and the 95-variant risk score with COPD exacerbations in 
subsets of individuals from UK Biobank, deCODE, four COPD case-control studies and two eMR 
studies (total 2,462 COPD exacerbation cases, 15,288 COPD non-exacerbation controls) and the Lung 
Health Study (100 exacerbation cases, 4,002 controls). There was no association of individual 
variants or genetic risk score with acute exacerbations of COPD (Supplementary Tables 12 and 13). 
To evaluate whether these variants showed disease-relevant associations in a non-European 
population, we studied 71 variants for which data were available in 7,116 COPD cases (20,919 
controls) and 5,292 exacerbation cases (1,824 controls) from the China Kadoorie Biobank cohort 
(CKB) (Supplementary Tables 10 to 13). The allelic risk score was associated with COPD susceptibility 
(OR per standard deviation change in risk score (95% CI) = 1.08 (1.04-1.11), P=4.2x10-6) suggesting 
some shared genetic contributions to COPD in European and East Asian descent populations. Thirty-
nine of the variants showed a consistent direction of effect on COPD in European and Chinese 
samples and seven of these were significant (P<0.05). Two signals were significant after correction 
for multiple testing (Supplementary Table 10c). 
To assess the impact of including individuals with asthma in a COPD case-control analysis, we tested 
for association with COPD in UK Biobank both before and after excluding individuals with self-
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reported doctor-diagnosed asthma and show that the effect size estimates were similar 
(Supplementary Figure 7). 
 
Implicated genes highlight pathways and druggable targets 
Gene expression and genotype data from lung, blood and multi-tissue resources were queried to 
identify whether the top variant at each of the 97 signals, or a proxy, were significantly associated 
with changes in expression of any gene (i.e. were an eQTL for any gene). Using this approach, and 
identification of deleterious variants within the association signal (Online methods, Supplementary 
Table 14), we implicated 234 genes with potentially causal effects on lung function (Supplementary 
Table 15). These 234 genes were enriched (False Discovery Rate (FDR) ≤5%) in elastic fibre pathways 
and in “signalling events mediated by the Hedgehog family”, the latter including CDON implicated by 
a novel intergenic signal (rs567508, between CDON and RPUSD4) on chromosome 11. We narrowed 
this group of 234 genes to 68 high-priority genes which were implicated via a deleterious variant or 
on stricter criteria for gene expression co-localisation (sentinel variant and top expression variant 
r2≥0.9, Table 2). We found that the 68 high-priority genes were overrepresented (FDR≤5%) among a 
number of gene ontology terms including SH3 domain binding, GTPase binding, actin binding and 
fibroblast migration (Supplementary Table 16). Alternative approaches to pathway analyses, which 
instead use all genome-wide association results, supported previous reports of enrichment of 
histone and systemic lupus erythematosus pathways14-16 and additional autoimmune and 
inflammatory pathways (Supplementary Table 17). Tests for tissue-specific enrichment of lung 
function signals overlapping histone marks identified enrichment in fetal lung, fetal heart and 
fibroblasts (H3K4me1), and stomach smooth muscle (H3K4me1 and H3K4me3) (Supplementary 
Table 18).  
Approved drugs, or drugs in development, target the protein products of 7 of the 234 genes 
(Supplementary Table 19a). This includes 3 high-priority genes CHRM3, SLC6A4 and CRHR1. CHRM3 
and SLC6A4 were both implicated by novel signals (rs6688537:C>A in an intron of CHRM3 and 
rs59835752:-/A in an intron of EFCAB5) and encode targets for drugs approved for the treatment of 
asthma and COPD (CHRM3, muscarinic acetylcholine receptor M3) and anxiety and depression 
(SLC6A4, serotonin transporter). CRHR1 (implicated by rs35524223:T>A in an intron of KANSL1) 
encodes the corticotropin releasing factor receptor 1 which is a target for compounds in 
development for the treatment of anxiety, depression and irritable bowel syndrome. The other 4 
genes include NDUFA12 (implicated by rs113745635:C>T in an intron of FGD6) encoding an NADH 
dehydrogenase which is a target for metformin hydrochloride, primarily used to treat type 2 
diabetes, and ITK (implicated by rs10515750 in an intron of CYFIP2) encoding a tyrosine-protein 
kinase, a target for the cancer drug Pazopanib.  
Using STRING32 to find proteins that interact with the proteins encoded by the high priority genes, 
we highlighted further druggable targets (Supplementary Table 19b). These included the PI3-kinase 
p110-delta subunit (part of the inositol phosphate metabolism pathway with INPP5E, which was 
implicated as a high-priority gene by rs10870202 in an intron of DNLZ, and a target for compounds in 
development for the treatment of COPD and asthma), and matrix metalloproteinases 1, 8 and 7 
(targets for doxycycline, which is an antibiotic and anti-malarial).  
10 
 
 Discussion  
 
In this study, the power gained by sampling from the extremes of a large biobank whilst retaining 
the power of a quantitative trait analysis, coupled with strategies to improve coverage of the 
genome and extensive follow-up, enabled a near-doubling of the number of signals of association 
with lung function identified to date. We further explored 95 variants, representing 43 novel signals 
and 52 previously reported signals, and showed that collectively these variants are strongly 
associated with COPD susceptibility.  
Using functional evidence from eQTL studies and deleterious variants to link signals to genes, we 
identified that 41 of the 97 lung function signals are also the strongest signals of association for 
expression of, or contain deleterious variants within, 68 genes (which we term “high-priority 
genes”). Amongst these, novel signals in or near FAM13A and ADAM19, both previously associated 
with lung function and COPD susceptibility9,33, along with evidence that these signals are themselves 
eQTLs for FAM13A and ADAM19, provide further evidence for FAM13A and ADAM19 themselves 
being the drivers of those signals. There was significant enrichment amongst the 68 genes for SH3 
domain (including ADAM19), GTPase and actin binding, and fibroblast migration, highlighting the 
potential importance of pathways relating to the cytoskeleton.  
The 68 genes identified as high-priority included genes at novel signals encoding targets for which 
there are approved drugs or drugs in development (Supplementary Table 19). Of note, the 
muscarinic acetylcholine receptor M3, encoded by CHRM3, is a well-characterised drug target for 
which many approved drugs exist, including for the treatment of asthma and obstructive lung 
disease. SLC6A4 encodes a serotonin transporter, a target for a number of drugs approved for 
treating depression and anxiety disorders, one of which (nortriptyline hydrochloride) has been 
trialed for use in inflammatory skin disorders (psoriasis and eczema); HTR4, which encodes a 
serotonin receptor, was identified in one of the earliest lung function GWAS13. INPP5E, identified as 
a high-priority gene for a novel signal of association with FVC (and FEV1) on chromosome 9, encodes 
inositol polyphosphate-5-phosphatase E, a component of the inositol phosphate metabolism 
pathway. Another component of the same pathway, phosphoinositide 3-kinase (PI3K) delta is a 
target of drugs under development for the treatment of a range of indications including COPD and 
asthma. Mutations in INPP5E cause ciliopathy (Joubert and MORM syndromes).  
Protective genetic variants that reduce the function or expression of a target protein could be 
mimicked by drugs and so are of particular interest. The minor allele (MAF 17%) at the novel signal in 
an intron of FAM13A was associated with decreased expression of FAM13A in lung tissue and 
reduced risk of COPD. This, together with recent evidence from a study of the Fam13a knockout 
mouse34, suggests that pharmacological inhibition of FAM13A may be protective.  
Extending our pathway analyses to all 234 genes implicated by gene expression or deleterious 
variants, we observed enrichment of genes related to “signalling events mediated by the Hedgehog 
family” pathway. Hedgehog signalling plays a crucial role in early development. Three members of 
this pathway, PTCH1, TGFB2 and HHIP, have been previously reported as likely causal genes 
underlying lung function association signals35. In this study, we additionally report PTHLH, encoding a 
parathyroid hormone-like hormone, and CDON¸ encoding a Hedgehog co-receptor, as likely causal 
genes (the latter at a novel signal). Of the 73 well-imputed variants available in children, we show 
correlation (r=0.62) between variant effect size estimates with those in adults. Should this pattern of 
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correlation apply across all 97 lung-function-associated variants, then this would suggest that many 
of these variants may act, at least in part, via effects on lung development. Elastic fibre pathways 
were over-represented; products of elastin degradation have been shown to be elevated during 
acute exacerbations of COPD 36,37. In addition, degradation of elastin by excess neutrophil-released 
elastase in the lung leads to emphysema in individuals with alpha-1 antitrypsin deficiency. CARD9, 
another high-priority gene at a novel signal, encodes an adaptor protein involved in neutrophil 
recruitment in respiratory fungal infection38. Tissue-specific enrichment of lung function signals 
overlapping H3K4me1 was seen in stomach smooth muscle. Although comparable H3K4me1 data 
were not available for airway smooth muscle, similar findings have been reported previously for 
rectal smooth muscle39. 
The 17q21.31 inversion has previously been associated with lung function. Custom imputation of 
additional structural variation at the locus, along with eQTL evidence and deleterious variants in the 
gene, suggested that KANSL1 may drive the association. Amongst the novel signals reported in this 
study, SNPs in an intron of EEFSEC on chromosome 3 are correlated with expression of nearby gene 
RUVBL1. Both KANSL1 and RUVBL1 encode members of histone modification complexes.  
A novel signal on chromosome 20 (rs72448466, intronic in ZGPAT), which showed association with 
FVC almost as strong as its association with FEV1, is an eQTL for the telomere gene, RTEL1. Although 
rs72448466:->GT was not the strongest eQTL for RTEL1 (r2=0.6 with the top eQTL variant), RTEL1 is 
of interest as it has recently been implicated in familial pulmonary fibrosis40. Variant rs72448466 has 
also been associated with inflammatory bowel disease, prostate cancer and atopic dermatitis. 
Our implication of genes of potential functional relevance to the 97 signals was based on gene 
expression data (eQTL) and associated deleterious variants within a gene. Although eQTL evidence 
currently gives the best in silico indication of which gene (or genes) might be functionally relevant to 
a signal, conclusive evidence for a causal relationship between SNP genotype and gene expression 
can only be obtained through direct molecular experiments. 
Six signals of association have been previously identified within the HLA region. Using a custom 
imputation approach, we identified the presence of alanine (compared to aspartic acid, valine or 
serine) at amino acid position 57 in HLA-DQβ1 as associated with decreased lung function and the 
main driver of signals in this region. The presence of alanine is also strongly associated with risk of 
type 1 diabetes41. 
The three lung function traits we studied are correlated. The overall and genetic correlations were: 
0.88 and 0.87 between FEV1 and FVC; 0.46 vs 0.35 between FEV1 and FEV1/FVC and; 0.038 and -0.17 
between FVC and FEV1/FVC (transformed traits, as studied in UK Biobank and SpiroMeta15, 
respectively). One might expect variants showing strongest association with FEV1 and FEV1/FVC to be 
of greatest relevance for COPD and genetic correlations of -0.76 and -0.9 have been reported 
between COPD and FEV1 and FEV1/FVC, respectively42. We show, however, that variants associated 
with one of these traits also tend to be associated with one of the other two lung function traits 
studied (for example, all but 2 signals for FVC are also associated (P<0.05) with FEV1, Supplementary 
Table 4). Although classification of COPD in UK Biobank was based on pre-bronchodilator 
spirometry, we have previously shown that this leads to minimal misclassification of moderate-
severe (GOLD 2-4) COPD43. The effect size estimates for COPD associations could be influenced by 
differences in case ascertainment between the follow-up studies. Motivated by avoidance of 
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potential winner’s curse bias for the 48 variants discovered using UK BiLEVE, we excluded UK BiLEVE 
from individual variant analyses. However, this excluded 9,563 moderate to severe COPD cases, and 
therefore the significance of COPD association tests for these variants should be interpreted with 
caution. Notably, we found effect size estimates only slightly smaller in deeply-characterised COPD 
case-control studies than in UK Biobank (OR per SD change in allelic risk score 1.36 compared to 
1.42). Whilst we show an appreciable proportion of COPD cases could be attributable to allelic risk 
scores above the first decile, great caution must be exercised in interpretation of population 
attributable risk fraction estimates given considerations of shared etiologic responsibility44. The lung 
function-associated variants we report were not associated with acute exacerbations of COPD. 
Although more powerful studies of exacerbations will be required, this suggests that different 
genetic mechanisms could underlie risk of acute exacerbations. 
A threshold of P<5x10-8 is a valid threshold for genome-wide significance in GWAS analyses of 
common variants45. Our genotyping and imputation strategy resulted in testing of 27.6 million 
variants of which 21.6 million had MAF<5% and 18.2 million had MAF<1%. Although all of our 43 
signals were common, had we adopted a stricter threshold for genome-wide significance, for 
example, P<1x10-8 (recommended in a recent report of significance thresholds in whole genome 
sequencing45), only two of our signals (rs10246303:A>T in the 3’ UTR of C1GALT1 on chromosome 7, 
and rs1698268:A>T near LINC00911 on chromosome 14) would not have reached significance. 
Thirty-nine of the 43 signals were additionally supported by statistically significant independent 
replication in stage 2 (P<0.05/43, Supplementary Table 3). 
In summary, our study provides the most comprehensive evidence yet regarding genetic variants 
associated with lung function and their association with susceptibility to COPD, with a more than 
threefold difference in COPD risk between highest and lowest allelic risk score deciles. Whilst 
translation of GWAS findings can take some years and requires extensive additional work, selecting 
genetically supported targets could double the drug development success rate17. The future clinical 
relevance of our findings include contributions towards understanding of disease pathogenesis, 
identification of drug targets for targeting or repositioning of drugs18, and potentially improved 
prediction of COPD or its subtypes. 
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Figure 1: Manhattan plots of genome-wide association results for FEV1 (top), FEV1/FVC (middle) and 
FVC (bottom). Previously reported signals are highlighted in dark blue (except signals with P>5x10-4 
in this study); and novel signals are coloured in red. Signals are highlighted for the trait with which 
they showed strongest association only. The red and blue lines correspond to the genome-wide 
significance level (P=5x10-8, -log10P=7.3) and the threshold used to select signals for follow up in 
stage 2 (P=5x10-7, -log10P=6.3) respectively. Labels show the nearest gene to the novel sentinel 
variants. There were 2 independent novel signals near CDC7 and TGFBR3 on chromosome 1 (labelled 
as CDC7/TGFBR3). See Supplementary Table 3 for full results. Image was created using a modified 
version of the R package qqman. 
Figure 2 Genetic Risk Score associations with COPD susceptibility (a) Forest plot of COPD results for 
the risk score analysis. Odds ratios per standard deviation of the risk score (~6 alleles) are presented 
for each study. Studies are grouped according to study design and phenotyping: “eMR”, electronic 
medical records, which used ICD codes to define COPD (DiscovEHR also used spirometry to refine the 
COPD definition); “case-control”, COPD case-control, which used post-bronchodilator spirometry to 
define COPD; “lung resection cohort”, which used a combination of pre and post-bronchodilator 
spirometry to define COPD; the Icelandic Biobank, deCODE, where cases were selected from a 
population based study and a study of COPD patients and defined using a spirometric definition, 
controls were selected as individuals within the cohort that were not known cases (no spirometric 
definition was used for controls); and UK Biobank (excluding UK BiLEVE), which used spirometry to 
define both COPD cases and controls. Further details are provided in the Supplementary Note.  (b) 
Odds ratios for spirometrically-defined COPD for weighted genetic risk score deciles in UK Biobank 
(10,547 cases, pre-bronchodilator % predicted FEV1<80% and FEV1/FVC<0.7, and 53,948 controls, 
FEV1/FVC>0.7 and % predicted FEV1>80%, weights derived from non-discovery populations). For 
each decile, odds ratios were obtained using a logistic regression adjusted for age, age2, sex, height, 
smoking status, pack-years and the first 10 ancestry principal components. The OR comparing the 
10th and the 1st decile in ever-smokers only was 3.35 (95% CI 2.93 to 3.84) and in never-smokers only 
was 4.27 (95% CI 3.61 to 5.06).  
 
Table 1: Stage 1 and stage 2 association results for the 43 novel signals of association with lung 
function. 
Where the discovery variant was not available in replication cohorts but a proxy with r2 > 0.7 was 
available, the proxy was used for replication in all cohorts (proxies are marked with * in rsid column). 
For discovery the standard errors and P values are genomic controlled except for conditional 
analyses (“Conditioned on” SNP is given in rsid column) where unadjusted standard errors and P 
values are given. Genomic controlled results were used for SpiroMeta. Unadjusted results were used 
for UK Biobank or UKHLS where genome-wide inflation factors were not available. Values are 
missing from stage 2 studies where there was quality control failure due to poor imputation (info < 
0.5) or low minor allele count (MAC < 3). In the meta-analysis of the Stage 2 replication cohorts the 
39 variants showing independent replication (Bonferroni correction for 81 tests: P <6.17×10-4) have P 
value in bold. Nearest gene gives either the nearest genes either side or the gene and location within 
the gene. Stage 1 association results (FEV1, FVC and FEV1/FVC) for the 54 signals of association that 
have been previously reported are given in Supplementary Table 4b. 
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Stage 1 (discovery in UK 
BiLEVE) 
Stage 2 Meta-analysis of stage 
1 and stage 2 
Top 
trait 
Rsid 
(conditioned 
on) 
Position 
b37 
Nearest 
gene(s) 
Non 
/coding 
allele 
Effect 
allele 
frequency beta se P 
UK 
Biobank 
beta 
UK 
Biobank 
se 
Spiro
Meta 
beta 
Spiro
Meta 
se 
UKHLS 
beta 
UKHLS 
se 
Meta 
beta 
Meta 
se 
Meta 
P 
beta 
 se 
Meta 
P 
FEV1/
FVC 
rs17513135 
1:4003568
6 
LOC10192951
6 (intron) 
C/T 23.15% -0.047 0.008 1.25E-09 -0.034 0.008 -0.025 0.009 -0.030 0.020 -0.033 0.006 1.17E-08 -0.038 0.005 2.31E-16 
FEV1/
FVC 
rs1192404 
(rs12140637) 
1:9206896
7 
CDC7/TGFBR
3 
A/G 16.21% -0.046 0.009 1.10E-07 -0.047 0.009 -0.046 0.010 -0.033 0.023 -0.050 0.007 9.31E-14 -0.048 0.005 6.09E-20 
FEV1/
FVC 
rs12140637 
1:9237451
7 
TGFBR3/BRD
T2 
C/T 31.30% -0.036 0.007 3.49E-07 -0.014 0.008 -0.019 0.008 -0.042 0.018 -0.020 0.005 1.46E-04 -0.026 0.004 1.18E-09 
FVC rs200154334 
1:1188620
70 
SPAG17/TBX
15 
AT/- 24.79% 0.054 0.008 9.70E-12 0.025 0.008 0.023 0.009 0.001 0.020 0.024 0.006 1.69E-05 0.034 0.005 8.20E-14 
FEV1/
FVC 
rs6688537 
1:2398505
88 
CHRM3 
(intron) 
C/A 50.60% -0.037 0.007 2.74E-08 -0.042 0.006 -0.023 0.008 -0.049 0.017 -0.039 0.005 4.05E-15 -0.038 0.004 6.72E-22 
FEV1/
FVC 
rs61332075 
2:2393165
60 
TRAF3IP1/AS
B1 
G/C 12.30% 0.060 0.010 2.93E-09 0.025 0.010 0.021 0.012 0.029 0.025 0.026 0.007 5.11E-04 0.038 0.006 2.55E-10 
FEV1/
FVC 
rs1458979 
3:5515067
7 
CACNA2D3/W
NT5A 
A/G 50.11% -0.035 0.007 1.52E-07 -0.021 0.006 -0.010 0.008 -0.031 0.017 -0.019 0.005 1.07E-04 -0.025 0.004 4.42E-10 
FVC rs1490265 
3:6745204
3 
SUCLG2 
(intron) 
C/A 70.79% 0.039 0.007 1.03E-07 0.022 0.007 0.008 0.008 0.036 0.018 0.019 0.005 3.27E-04 0.026 0.004 1.58E-09 
FEV1/
rs2811415 
3:1279915 EEFSEC 
A/G 84.04% -0.057 0.009 2.64E-10 -0.017 0.009 -0.023 0.010 -0.041 0.022 -0.023 0.007 4.53E-04 -0.035 0.005 5.52E-11 
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FVC 27 (intron) 
FEV1/
FVC 
rs56341938* 
3:1687158
08 
LOC10050766
1/MECOM 
A/G 51.34% 0.034 0.007 3.38E-07 0.037 0.006 0.013 0.008 - - 0.027 0.005 1.97E-08 0.029 0.004 4.52E-14 
FEV1/
FVC 
rs13110699 
(rs2045517) 
4:8981569
5 
FAM13A 
(intron) 
T/G 82.51% -0.045 0.008 1.29E-07 -0.037 0.008 -0.030 0.009 -0.014 0.024 -0.035 0.006 7.80E-09 -0.038 0.005 7.86E-15 
FVC rs91731 
5:3333431
2 
LOC340113/T
ARS 
C/A 90.53% -0.070 0.011 8.10E-10 -0.031 0.011 -0.047 0.013 0.000 0.028 -0.038 0.008 7.88E-06 -0.049 0.007 4.31E-13 
FEV1/
FVC 
rs1551943 
5:5219503
3 
ITGA1 (intron) G/A 23.01% -0.052 0.008 3.12E-11 -0.041 0.008 -0.019 0.009 -0.031 0.020 -0.035 0.006 2.35E-09 -0.041 0.005 1.92E-18 
FVC rs2441026 
5:5344449
8 
ARL15 (intron) C/T 46.27% 0.034 0.007 4.59E-07 0.023 0.006 0.025 0.008 0.006 0.017 0.024 0.005 6.59E-07 0.027 0.004 2.75E-12 
FEV1/
FVC 
rs7713065 
5:1317883
34 
C5orf56 
(intron) 
A/C 73.67% 0.039 0.007 2.21E-07 0.029 0.007 0.014 0.008 0.017 0.019 0.024 0.005 8.29E-06 0.029 0.004 2.77E-11 
FEV1 rs3839234 
5:1485966
93 
ABLIM3 
(intron) 
G/- 47.01% -0.038 0.007 8.87E-09 -0.023 0.006 -0.014 0.008 0.001 0.017 -0.019 0.005 7.71E-05 -0.026 0.004 4.48E-11 
FEV1/
FVC 
rs10515750 
(rs1990950) 
5:1568100
72 
CYFIP2 
(intron) 
C/T 7.18% -0.063 0.012 2.61E-07 -0.050 0.012 -0.040 0.014 -0.033 0.032 -0.048 0.009 2.62E-07 -0.054 0.007 5.26E-13 
FEV1/
FVC 
rs28986170 
(rs2070600 
rs9272528*) 
6:3155615
5 
LST1 (intron) -/AA 7.52% 0.075 0.013 2.30E-08 0.034 0.014 - - 0.096 0.036 0.048 0.014 6.49E-04 0.063 0.010 1.56E-10 
FEV1 rs114229351 
6:3264841
8 
HLA-
DQB1/HLA-
T/C 17.53% -0.046 0.009 1.15E-07 -0.026 0.008 - - -0.045 0.026 -0.030 0.008 1.78E-04 -0.037 0.006 2.12E-10 
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(rs34864796) DQA2  
FEV1/
FVC 
rs141651520 
6:7367009
5 
KCNQ5 
(intron) 
TTCTAT
/- 
20.10% 0.042 0.008 3.38E-07 0.049 0.008 0.026 0.009 0.025 0.020 0.042 0.006 5.49E-12 0.042 0.005 9.93E-18 
FEV1/
FVC 
rs10246303 7:7286445 
C1GALT1 (3’ 
UTR) 
A/T 41.74% -0.034 0.007 4.42E-07 -0.013 0.006 -0.016 0.008 -0.019 0.017 -0.016 0.005 1.29E-03 -0.022 0.004 2.35E-08 
FEV1/
FVC 
rs72615157 
7:9963596
7 
ZKSCAN1 (3’ 
UTR) 
G/A 16.73% 0.046 0.009 2.68E-07 0.015 0.009 0.030 0.010 0.030 0.022 0.024 0.007 2.56E-04 0.032 0.005 1.98E-09 
FEV1 rs12698403 
7:1561272
46 
LOC389602/L
OC285889 
G/A 44.36% -0.036 0.007 7.43E-08 -0.025 0.006 -0.025 0.008 -0.012 0.017 -0.026 0.005 1.43E-07 -0.029 0.004 1.11E-13 
FEV1 rs7872188 9:4124377 GLIS3 (intron) C/T 40.17% -0.038 0.007 1.80E-08 -0.019 0.007 -0.020 0.008 0.005 0.017 -0.019 0.005 1.41E-04 -0.026 0.004 1.59E-10 
FVC 
rs10870202 
(rs10858246) 
9:1392574
11 
DNLZ (intron) T/C 50.01% -0.033 0.006 3.25E-07 -0.016 0.006 -0.017 0.008 -0.027 0.017 -0.019 0.005 1.54E-04 -0.024 0.004 9.32E-10 
FEV1/
FVC 
rs3847402 
10:302678
10 
SVIL/KIAA146
2 
G/A 40.57% -0.036 0.007 1.00E-07 -0.017 0.007 -0.027 0.008 -0.007 0.017 -0.021 0.005 3.84E-05 -0.027 0.004 7.72E-11 
FVC rs7095607 
10:699573
50 
MYPN (intron) G/A 49.52% -0.037 0.007 3.93E-08 -0.021 0.006 -0.029 0.008 -0.030 0.017 -0.027 0.005 2.26E-08 -0.031 0.004 8.67E-15 
FEV1 rs2509961 
11:623109
09 
AHNAK 
(intron) 
T/C 38.21% 0.036 0.007 1.68E-07 0.030 0.007 0.017 0.008 0.025 0.017 0.027 0.005 1.07E-07 0.030 0.004 1.49E-13 
FEV1 rs145729347* 
11:864427
33 
ME3/PRSS23 G/C 15.08% -0.056 0.009 1.67E-09 -0.020 0.009 -0.016 0.010 - - -0.018 0.007 5.36E-03 -0.031 0.005 8.58E-09 
FEV1 rs567508 
11:126008
910 
CDON/RPUS
D4 
G/A 84.96% 0.050 0.009 1.11E-07 0.029 0.009 0.013 0.010 0.053 0.024 0.026 0.007 1.08E-04 0.034 0.005 4.77E-10 
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FEV1 rs1494502 
12:658246
70 
MSRB3 
(intron) 
A/G 36.20% 0.036 0.007 2.72E-07 0.020 0.007 0.012 0.008 0.030 0.017 0.019 0.005 1.33E-04 0.025 0.004 9.80E-10 
FEV1/
FVC 
rs113745635 
12:955547
71 
FGD6 (intron) C/T 21.20% -0.050 0.008 3.47E-10 -0.039 0.008 -0.018 0.009 -0.061 0.020 -0.036 0.006 1.41E-09 -0.041 0.005 8.46E-18 
FVC rs35506 
12:115500
691 
TBX3/MED13
L 
T/A 71.25% 0.037 0.007 4.31E-07 0.021 0.007 0.019 0.008 0.011 0.018 0.021 0.005 1.08E-04 0.027 0.004 9.87E-10 
FEV1/
FVC 
rs1698268 
14:843096
64 
LINC01467/LI
NC00911 
A/T 29.44% -0.039 0.007 1.12E-07 -0.023 0.007 -0.003 0.010 
0.000 
 
0.018 -0.016 0.006 4.20E-03 -0.025 0.005 3.19E-08 
FEV1/
FVC 
rs72724130 
15:419776
90 
MGA (intron) A/T 5.70% -0.075 0.014 2.05E-07 -0.046 0.014 -0.039 0.021 0.007 0.035 -0.043 0.012 2.62E-04 -0.056 0.009 9.58E-10 
FEV1/
FVC 
rs12591467 
(rs10851839) 
15:717883
87 
THSD4 
(intron) 
C/T 68.38% 0.037 0.007 6.45E-08 0.021 0.007 0.011 0.008 0.030 0.018 0.019 0.005 2.17E-04 0.026 0.004 5.65E-10 
FEV1/
FVC 
rs66650179 
15:842616
89 
SH3GL3 
(intron) 
A/- 81.34% -0.048 0.009 2.60E-08 -0.030 0.008 - - -0.035 0.021 -0.036 0.008 1.79E-05 -0.042 0.006 3.71E-12 
FEV1/
FVC 
rs62070270* 
17:282639
80 
EFCAB5 
(intron) 
A/G 45.65% -0.041 0.007 6.71E-10 -0.036 0.006 -0.021 0.008 - - -0.030 0.005 8.00E-10 -0.034 0.004 7.29E-18 
FEV1/
FVC 
rs11658500 
17:368868
28 
CISD3 (intron) G/A 14.16% -0.051 0.009 4.70E-08 -0.031 0.009 -0.011 0.011 -0.069 0.025 -0.029 0.007 5.11E-05 -0.037 0.006 7.22E-11 
FVC rs6140050 
20:663290
1 
CASC20/BMP
2  
C/A 63.34% 0.040 0.007 5.95E-09 0.026 0.007 0.028 0.008 -0.011 0.017 0.026 0.005 5.23E-07 
0.031 
 
0.004 6.39E-14 
FEV1 rs72448466 
20:623636
40 
ZGPAT 
(intron) 
GT/- 67.28% -0.038 0.007 1.09E-07 -0.020 0.007 -0.029 0.008 -0.032 0.017 -0.027 0.005 3.68E-07 
-0.030 
 
0.004 4.31E-13 
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FEV1 rs11704827 
22:184502
87 
MICAL3 
(intron) 
A/T 23.14% 0.049 0.008 6.08E-10 0.021 0.008 0.021 0.009 0.047 0.020 0.025 0.006 1.44E-05 0.033 0.005 8.32E-13 
FEV1 rs2283847 
22:281813
99 
MN1 (intron) C/T 55.51% -0.038 0.007 2.40E-08 -0.026 0.007 -0.014 0.008 -0.003 0.021 -0.021 0.005 3.65E-05 -0.027 0.004 3.41E-11 
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Table 2 Genes implicated as high-priority genes for novel genome-wide significant and previously-
reported signals using expression data and functional annotation. #Variant did not reach P<5.15x10-4 
(Bonferroni corrected P value for 97 tests) in this study for any trait. *Gene implicated as it 
contained a deleterious variant (Supplementary Table 14); all other genes implicated by co-
localisation of GWAS and eQTL signal. (*) implicated by both co-localisation of eQTL and GWAS, and 
a deleterious variant. All 234 genes implicated are listed in Supplementary Table 15. 
Genome-wide 
significant trait 
(additional traits 
with P<5.15x10-4) 
Variant ID (position b37) Nearest gene(s) High-priority genes 
Novel signals 
FEV1/FVC (FVC) rs17513135 (chr1:40,035,686) LOC101929516 (intron) PABPC4 
FEV1/FVC (FEV1) rs6688537 (chr1:239,850,588) CHRM3 (intron) CHRM3 
FEV1/FVC (FEV1) rs2811415 (chr3:127,991,527) EEFSEC (intron) RUVBL1 
FEV1/FVC (-) rs13110699 (chr4:89,815,695) FAM13A (intron) FAM13A 
FEV1 (FVC, FEV1/FVC) rs3839234 (chr5:148,596,693) ABLIM3 (intron) GRPEL2, ABLIM3 
FEV1/FVC (FEV1) rs10515750 (chr5:156,810,072) CYFIP2 (intron) ADAM19 
FEV1/FVC (FEV1) rs200003338 (chr6:31,556,155) LST1 (intron) MICB*, MICA* 
FEV1/FVC (FEV1) rs10246303 (chr7:7,286,445) C1GALT1 (3’ UTR) C1GALT1 
FVC (FEV1) rs10870202 (chr9:139,257,411) DNLZ (intron) INPP5E, CARD9 
FVC (FEV1) rs7095607 (chr10:69,957,350) MYPN (intron) MYPN* 
FEV1 (FVC) rs2509961 (chr11:62,310,909) AHNAK (intron) ROM1, EML3, MTA2, 
GANAB, C11orf83* 
FEV1/FVC (-) rs59835752 (chr17:28,265,330) EFCAB5 (intron) EFCAB5, CRYBA1, SSH2, 
SLC6A4 
FEV1/FVC (FEV1) rs11658500 (chr17:36,886,828) CISD3 (intron) CISD3* 
FEV1 (FVC) rs72448466 (chr20:62,363,640) ZGPAT (intron) LIME1 
 Previously-reported signals 
FEV1 (FVC) rs6681426 (chr1:150,586,971) MCL1/ENSA GOLPH3L 
FEV1/FVC (-) rs4328080 (chr1:219,963,088) LYPLAL1/RNU5F-1 SLC30A10 
FEV1 (FVC, FEV1/FVC) rs2571445 (chr2:218,683,154) TNS1 (exon) TNS1* 
FEV1/FVC (-) rs10498230 (chr2:229,502,503) SPHKAP/PID1 SPHKAP 
FVC (FEV1) rs1595029 (chr3:158,241,767) RSRC1 (intron) RSRC1 
FEV1 (FVC, FEV1/FVC) rs10516526 (chr4:106,688,904) GSTCD (intron) INTS12, GSTCD, NPNT 
FEV1/FVC (FEV1, FVC) rs34712979 (chr4:106,819,053) NPNT (intron) NPNT 
FEV1/FVC (FEV1) rs138641402 (chr4:145,445,779) GYPA/HHIP-AS1 HHIP 
FEV1/FVC (-) rs153916 (chr5:95,036,700) SPATA9/RHOBTB3 RHOBTB3 
FEV1/FVC (FEV1) rs1990950 (chr5:156,920,756) ADAM19 (intron) ADAM19 
FEV1 (FVC, FEV1/FVC) rs34864796 (chr6:27,459,923) ZNF184/LINC01012 OR2B2* 
FEV1/FVC (FEV1) rs2857595 (chr6:31,568,469) NCR3/AIF1 MICB* 
FEV1/FVC (-) rs2070600 (chr6:32,151,443) AGER (exon) AGER(*) 
FEV1 (FVC, FEV1/FVC) rs114544105 (chr6:32,635,629) HLA-DQB1/HLA-DQA2 HLA-DQB1*, APOM, 
RNF5 
FEV1/FVC (FEV1) rs113096699 (chr6:142,745,883) GPR126 (intron) GPR126 
FEV1/FVC (-) rs148274477 (chr6:142,838,173) GPR126/LOC153910 GPR126* 
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FVC (FEV1) rs10858246 (chr9:139,102,831) QSOX2 (intron) QSOX2 
FVC (FEV1) rs2348418 (chr12:28,689,514) CCDC91 (intron) FLJ35252 
FEV1/FVC# (-) rs11172113 (chr12:57,527,283) LRP1 (intron) LRP1 
FEV1# (-) rs7155279 (chr14:92,485,881) TRIP11 (intron) ATXN3 
FEV1# (-) rs117068593 (chr14:93,118,229) RIN3 (exon) RIN3(*) 
FEV1/FVC (FEV1) rs10851839 (chr15:71,628,370) THSD4 (intron) THSD4 
FEV1/FVC (-) rs12447804 (chr16:58,075,282) MMP15 (intron) MMP15 
FEV1/FVC (FEV1) rs3743609 (chr16:75,467,021) CFDP1 (intron) TMEM170A, BCAR1, 
CFDP1 
FEV1 (FVC, FEV1/FVC) rs35524223 (chr17:44,192,590) KANSL1 (intron) KANSL1(*), MAPT(*), 
ARL17B, ARL17A, 
LRRC37A4, NUDT1, 
LRRC37A, CRHR1, 
LRRC37A2, ARHGAP27, 
FMNL1, PLEKHM1, 
WNT3, NSF, SPPL2C* 
FEV1 (FVC) rs7218675 (chr17:73,513,185) TSEN54 (intron) CASKIN2, TSEN54* 
FEV1/FVC (-) rs113473882 (chr19:41,124,155) LTBP4 (intron) LTBP4* 
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Online Methods  
Study Governance 
UK Biobank has ethical approval from the NHS National Research Ethics Service (Ref 11/NW/0382). 
Informed consent was obtained from all participants. All other studies were approved by an 
appropriate ethics committee or data protection authority (Supplementary Note). 
Stage 1 study sample selection 
A genome-wide discovery study for variants associated with lung function measures was performed 
in 48,943 individuals from the UK BiLEVE16 subset of UK Biobank (UK BiLEVE, stage 1). In brief, UK 
Biobank comprised 502,682 individuals of whom 275,939 were of self-reported European-ancestry 
and had ≥2 Forced Expired Volume in 1s (FEV1) and Forced Vital Capacity (FVC) measures 
(Vitalograph Pneumotrac 6800, Buckingham, UK) passing ATS/ERS criteria46. Based on the best 
(highest) available FEV1 measurement, 50,008 individuals from groups with extreme low (n=10,002), 
near-average (n=10,000) and extreme high (n=5,002) % predicted FEV1 were selected from amongst 
never-smokers (total n=105,272) and the same numbers from amongst the heavy-smokers (mean 35 
pack-years of smoking, total n=46,758). FEV1, FVC and FEV1/FVC distributions are summarised in 
Supplementary Figure 8. Genotyping was undertaken using the Affymetrix Axiom UK BiLEVE array16 
and imputed to the 1000 Genomes Project Phase 147 and UK10K48,49 combined panel. A total of 
27,624,732 imputed or directly genotyped autosomal variants with imputation quality (info) >0.5 
and minor allele count (MAC) ≥3 were included in the analysis. In total, 48,943 unrelated individuals 
passed all quality control steps and were used in this analysis. 
Association testing and selection of signals from stage 1 for follow-up in stage 2 
Power calculations were undertaken using Quanto (see URLs) (Supplementary Figure 9). For stage 1, 
genome-wide association studies of FEV1, FVC and FEV1/FVC were undertaken separately in heavy-
smokers and never-smokers and then meta-analysed for each trait. Linear regression of age, age2, 
sex, height, the first 10 principal components of genetic ancestry and pack years of smoking (in 
smokers) on each trait was undertaken and residuals were ranked and transformed to inverse 
normally distributed Z-scores. For the first 26 lung function variants reported11,13,14,50 we showed 
Stage 2 effect size estimates14 were comparable with those from inverse normally distributed Z-
scores in UK BiLEVE (Supplementary Figure 10). Subsequently these Z-scores were used for genome-
wide association testing using an additive genetic model (SNPTEST v2.5). The full genome-wide stage 
1 results are available via UK Biobank (see URLs). 
From each of the three discovery GWAS, signals were selected for follow-up in stage 2 if they met an 
initial threshold of P<5x10-7. Low MAC variants (MAC between 3 and 20), were selected for follow-up 
only if the imputation quality (info) exceeded 0.8. Independence of signals was determined as 
follows: the most strongly associated (P<5x10-7) variant within a 1Mb region was selected as a 
putative signal and then the analysis repeated for that 1Mb region conditioning on the most strongly 
associated variant. Any variant which then had a conditional P<5x10-7 was then assigned as a 
secondary putative signal and also included in the conditional analysis. This was repeated until no 
variants with P<5x10-7 remained within the 1Mb region. Results were confirmed using a joint 
conditional analysis (GCTA51) and visual inspection of region plots. Previously reported signals were 
not included in the final list of putative signals to be taken for follow-up in stage 2. Where novel 
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signals for different traits were in linkage disequilibrium (r2 > 0.2), the variant for the trait with the 
most significant association was followed up. Due to the extended LD structure in the MHC region, 
conditional analyses and GCTA were run over a 9Mb region (chr6:24,126,750-33,126,689). Two pairs 
of signals previously reported as being independent (rs16909859:G>A11 and rs16909898:A>G14 in 
PTCH1, and rs34712979:G>A16 and rs6856422:T>G15, in NPNT) were found to be correlated in our 
data. 
Stage 2 – follow-up in independent studies (quantitative lung function) 
Putative novel signals of association from stage 1 were followed up in three independent sets of 
samples (stage 2): (i) an independent subset of UK Biobank participants (UK Biobank, n=49,727), (ii) a 
population-based consortium (SpiroMeta, n=38,199)15 and (iii) UK Households Longitudinal Study 
(UKHLS, n=7,449). We did not include these studies in Stage 1 as: (ii) was to be utilised for 
independent replication and; (i) and (iii) were not yet available when Stage 1 was undertaken. Each 
signal was followed-up only for the trait with which it was most strongly associated in Stage 1. The 
first tranche of genotype data and imputation output (merged 1000 Genomes Project Phase 3 and 
UK10K imputation panel) from UK Biobank was released May 2015 (see URLs) and comprised the 
49,979 individuals originally genotyped for UK BiLEVE (an unrelated subset of 48,943 of which were 
used as discovery in this study) and an additional 102,757 individuals selected at random from the 
entire UK Biobank. From these 102,757 individuals, we initially selected 51,117 samples that had 
lung function measurements (FEV1 and FVC) meeting ATS/ERS criteria and had covariates age, sex, 
height, principal components and smoking status recorded. Following further exclusion of individuals 
with sex mismatches (n=41), individuals of non-European ancestry (based on k-means clustering of 
principal components 1 and 2 with 4 clusters, n=124) and one individual from each pair of related 
samples (KING relatedness > 0.088 [2nd degree], n=1,225), a total of 49,727 individuals remained for 
analysis.   
The details of the SpiroMeta consortium analysis (including contributing studies, spirometry details 
and methods) are described elsewhere15. In brief, this was an inverse variance weighted fixed effects 
meta-analysis of 17 studies with imputation to 1000 Genomes Project Phase 1 reference panel. 
Within each study, FEV1, FVC and FEV1/FVC were adjusted for age, age2, sex, height and population 
structure, separately for ever and never-smokers. Inverse normal transformed residuals were then 
tested for association within each smoking stratum assuming an additive genetic effect and then 
meta-analysed. Genomic control was applied to account for residual population structure. We only 
included SpiroMeta meta-analysis results in the meta-analysis in this study if Neffective > 70% (i.e. 
>70% of 38,199), where Neffective is the effective sample size after scaling for imputation quality15. 
Summary statistics of a GWAS of FEV1, FVC and FEV1/FVC in 7,449 individuals were available from 
UKHLS (Supplementary Note). SNPs were genotyped using the Illumina Infinium HumanCoreExome 
BeadChip Kit and imputed against the same 1000 Genomes Project + UK10K combined imputation 
panel as used in discovery in this study. Association testing was performed separately for ever and 
never-smokers with covariates age, age2, sex height and ancestry principal components, as for Stage 
1. We only included UKHLS results in the meta-analysis in this study if imputation info >0.5 and MAC 
>=3. 
Meta-analysis of stage 1 and stage 2 
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All meta-analyses were undertaken using fixed effects inverse variance weighting which takes 
directionality of association into account. Effect estimates for all variants followed up in stage 2 were 
meta-analysed across the three stage 2 studies and then the combined result was meta-analysed 
with stage 1 results. Where the discovery variant was not present in any stage 2 study, a proxy 
(r2>0.8) that was available in all stage 1 and stage 2 studies was used. We report signals with 
association P<5x10-8 in the meta-analysis of stages 1 and 2 as novel signals of association with lung 
function.  
Assessment of stage 1 and stage 2 sample overlap by LD score regression 
LD score regression was used to assess the extent of confounding. Absence of significant confounding 
indicates that factors such as sample overlap and/or population stratification are not evident. Pre-
computed LD scores from a European population were used (see URLs), based on genotypes for 
1,293,150 HapMap3 SNPs in samples from the 1000 Genomes Project EUR population. Association 
results were filtered (info > 0.9 and MAF > 1%) before running LD score regression on (i) 3 pairwise 
meta-analyses of results from UK BiLEVE (stage 1) and UK Biobank (stage 2), UK BiLEVE and 
SpiroMeta and UK Biobank and SpiroMeta; (ii) bivariate analyses of the 3 pairs of cohorts. 
Effect sizes in adults and children 
The effects of variants on lung function in children were also tested in 5,062 children from ALSPAC 
(mean age 8.6) and 1,220 children from the Raine study (mean age 8.1). Data were available for 81 
of the 97 variants (a proxy variant with r2>0.7 was used for 11 signals) with imputation quality >0.5 
of which 73 had imputation quality >0.8 (71 variants in ALSPAC and 35 in the Raine study). 
Association results from the two cohorts were combined using inverse variance weighted meta-
analysis. A weighted risk score was approximated using pooled single SNP results, as described in 
Dastani et al52, and weights obtained using estimated effect sizes from either SpiroMeta15 summary 
data (for SNPs discovered in UK Biobank), or from UK Biobank (for SNPs discovered elsewhere). The 
risk score was tested for the three lung function traits: FEV1, FVC and FEV1/FVC.    
Refinement of signals 
A Bayesian method53 was used to fine-map lung function-associated signals to the set of variants 
that were 95% likely to contain the underlying causal variant (assuming that the causal variant has 
been analysed). This was undertaken for novel signals and for previously-reported signals which 
reached P<10-5 in the stage 1 results. Following van de Bunt et al.54 we set the value of a prior W=0.4 
in the approximate Bayes Factor formula. Signals in the HLA were not included. 
We re-imputed our 48,943 discovery samples across the HLA (chr6:29,607,078-33,267,103 (b37)) 
using IMPUTE2 v2.3.1 with a reference panel incorporating classical HLA alleles and amino acid 
changes55. The reference panel contained haplotypes for 5,225 samples from the type 1 diabetes 
genetics consortium (T1DGC) across 8,961 biallelic variants comprised of 5,863 directly genotyped 
biallelic SNPs and 3,098 surrogate biallelic variants encoding multiallelic SNPs, indels, classical HLA 
alleles and amino acid changes. Association testing was then undertaken as described for stage 1 for 
FEV1 and FEV1/FVC.  
Effects of lung function associated variants on other traits 
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To identify whether the novel and previously reported lung function-associated variants had been 
reported in previous GWAS as associated with traits other than lung function and COPD, we queried 
the GWAS Catalog56 (last update: 13/03/2016, downloaded on 17/03/16) and GRASP57 (v2.0, 
downloaded on 17/03/16) for genome-wide significant (P<5x10-8) signals using the 95% credible set 
(if calculated) or all proxy SNPs (r2>0.8) within 2Mb of the top variant in our data. 
Clinical relevance – COPD susceptibility and risk of COPD exacerbations in European and Chinese 
populations 
The effect on COPD susceptibility of up to 95 out of the 97 lung function-associated signals was 
tested in the COPD study at deCODE Genetics (deCODE COPD study) (1,964 COPD cases and 142,262 
controls for single-variant analyses and 1,248 COPD cases and 74,700 controls for risk score 
analyses), in three lung resection studies: Groningen, Laval and UBC (310 COPD cases and 332 
controls), in the following COPD case-control studies: COPDGene Study (2,812 COPD cases and 2,534 
controls), Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) 
(1,736 COPD cases and 176 controls), National Emphysema Treatment Trial (NETT) and Normative 
Aging Study (NAS) (NETT/NAS, 376 COPD cases and 435 controls) and the Norway GenKOLS study 
(Genetics of Chronic Obstructive Lung Disease) (854 cases and 805 controls), in the following eMR 
studies: Mount Sinai BioMe Biobank (BioMe, 207 COPD cases and 1,817 controls) and Geisinger-
Regeneron DiscovEHR Study (DiscovEHR, 1,280 COPD cases and 13,321 controls for single-variant 
analyses and 1,264 COPD cases and 13,032 controls for risk score analyses), and in UK Biobank (not 
including UK BiLEVE samples, 984 cases and 26,561 controls in total) and UK BiLEVE (9,563 
moderate-severe cases, 27,387 controls). rs7050036, located in chromosome X, and 
chr12:114743533, with MAF= 0.15%, were not present in most studies and therefore were excluded 
from these analyses, bringing the 97 signals to 95. Of the 95 signals, 47 signals were previously 
discovered independently of UK BiLEVE and were tested for association using all available COPD 
cases and controls (20,086 COPD cases and 215,630 controls). The remaining 48 signals were 
discovered using UK BiLEVE data and so were tested for association using 10,523 COPD cases and 
188,243 controls (UK BiLEVE excluded). The effect on risk of COPD exacerbation was additionally 
tested in the Lung Health Study (LHS) (100 COPD exacerbation cases and 4,002 COPD controls) as 
well as subsets of UK Biobank (including UK BiLEVE, 647 cases and 9,900 controls), COPDGene (557 
cases and 2,255 controls), ECLIPSE (278 cases and 1,458 controls), NETT/NAS (87 cases and 277 
controls), GenKOLS (120 cases and 734 controls), BioMe (8 cases and 199 controls) and DiscovEHR 
(774 cases and 472 controls). Analyses of the effect of lung function variants on COPD susceptibility 
and on risk of COPD exacerbations in a Chinese ancestry population were undertaken using the 
China Kadoorie Biobank prospective cohort (CKB) within which data were available for 71 (single 
variant analyses) or 70 (risk score analyses) of the 95 variants (or proxies) for analyses of COPD 
susceptibility (7,116 COPD cases and 20,919 controls) and risk of COPD exacerbation (5,292 cases 
and 1,824 controls). Further details of all studies, including case and control definitions are in the 
Supplementary Note and Supplementary Table 20. 
To test the single variant associations with COPD susceptibility and risk of exacerbation, logistic 
regression using age, age2, sex, and height as covariates (unless otherwise indicated, Supplementary 
Note) and assuming an additive genetic effect was used. To test the joint effect of these variants, 
risk alleles in the subset of the 95 signals with data available in each study (from 86 to 95) were 
summed to create an unweighted genetic risk score and logistic regression was used to test the 
29 
 
effect of the risk score, as a continuous variable, on COPD status and COPD exacerbation status 
(adjusted for age, age2, sex and height, unless otherwise indicated, Supplementary Note). Results, 
both from single variant and risk scores, were meta-analysed separately for studies where similar 
study design and phenotyping was used: eMR, case-control and lung resection, and results were also 
meta-analysed across studies. Inverse variance weighted meta-analysis was used. In CKB, analyses 
were adjusted for sex, age, age2, height, region (n=10) and disease status (n=5) and final results were 
GC-corrected based on genome-wide inflation estimates. Heterogeneity was tested using I2(ref 58). 
We calculated odds ratios for spirometrically-defined COPD for weighted risk score deciles in UK 
Biobank (incorporating UK BiLEVE, 10,547 cases, pre-bronchodilator % predicted FEV1<80% and 
FEV1/FVC<0.7, and 53,948 controls, FEV1/FVC>0.7 and % predicted FEV1>80%). The weighting of the 
risk score was undertaken using COPD logOR calculated in studies free of winner’s curse bias 
(Supplementary Table 21). We scaled the logOR, so that the weights added up to 95. 
Population attributable risk fraction calculation 
The population attributable risk fraction (PARF) was calculated using the formula below 
𝑃𝐴𝑅𝐹 =
𝑃(𝐸)(𝑂𝑅 − 1)
1 + 𝑃(𝐸)(𝑂𝑅 − 1)
 
 
where 𝑃(𝐸) is the probability of the exposure, in this case the probability of having more risk alleles 
than those in the lowest decile of the risk score (𝑃(𝐸) =0.9), and the 𝑂𝑅 refers to the odds of having 
COPD for individuals in deciles 2 to 10 of the risk score compared to the odds of having COPD for 
individuals in the lowest decile (decile 1) of the risk score. The 𝑂𝑅𝑠 were calculated separately in 
ever and heavy-smokers using a logistic regression adjusted for age, age2, sex, height and the first 10 
ancestry principal components, and an additional pack-years adjustment for heavy-smokers, and 
were then meta-analysed using inverse variance weighting. Confidence intervals were estimated 
using the formula above with the lower and upper bound of the meta-analysed OR estimated by 
logistic regression. These analyses were run using UK Biobank data and the COPD case definition 
described above: individuals with % predicted FEV1<80% and FEV1/FVC<0.7 were selected as COPD 
cases and those with FEV1/FVC>0.7 and % predicted FEV1>80% were selected as controls. 
Implication of causal genes 
In order to implicate the likely causal gene (or genes) for each of the novel and previously-reported 
signals (97 in total), we employed functional annotation and analysis of gene expression data. All 
variants within 25kb, variants within 500kb and with r2>0.5 of the top SNP at each signal and variants 
within 1Mb and with r2>0.8 with the top SNP were annotated using ENSEMBL’s Variant Effect 
Predictor (VEP). A variant was labelled as deleterious if it was a missense coding variant that was 
annotated as ‘deleterious’ by SIFT, ‘probably damaging’ or ‘potentially damaging’ by PolyPhen-2, had 
a CADD scaled score ≥ 20 (CADD_PHRED ≥ 20), or had a GWAVA score > 0.5. The deleterious variants 
were each, in turn, included as a covariate in the association analysis for the top SNP. If inclusion of 
the deleterious variant as a covariate reduced the association signal for the top SNP such that 
P>0.01, that deleterious variant was deemed to explain part of the signal. If annotation (e.g. a coding 
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variant) implicated a specific gene, then the gene was classified as a high-priority gene for the 
relevant signal. 
At each signal, the sentinel SNP and top proxies with r2>0.4 and within 2Mb, no limit on number of 
proxies, were used to query 3 eQTL resources; lung eQTL23,24,59, blood eQTL60 and GTEx61 (artery 
(aorta and tibia), adrenal gland, colon sigmoid, esophagus (gastroesophageal junction and mucosa), 
transformed fibroblasts, lung, spleen, skin (sun exposed lower leg), stomach, testis, thyroid, whole 
blood). A False Discovery Rate (FDR) of 10% was used as a threshold for significance in the lung and 
blood eQTL datasets and 5% in GTEx (due to large number of different tissues and cells, and small 
sample size). A gene was classified as a potential causal gene if the sentinel SNP or proxy (r2>0.4) 
showed significant evidence of being an eQTL signal for that gene. Genes were further classified as 
high-priority genes if the variant most strongly associated with the lung function traits (or a proxy 
with r2>0.9) was also the variant most strongly associated with expression of the gene in one or 
more of the eQTL datasets (i.e. there was co-localisation of the lung function associated SNP and the 
gene expression associated SNP). Due to extended linkage disequilibrium across the MHC region, 
only high-priority genes were identified for the signals in the MHC. 
Pathway analyses 
The genes implicated for each signal (high-priority genes only and all genes) were tested for 
enrichment of gene sets and pathways using ConsensusPathDB62. Pathways or gene sets represented 
entirely by genes implicated by the same association signal were excluded. Pathways or gene sets 
represented by 2 or more genes from the same association signal were flagged. Pathway enrichment 
using all genome-wide P values was undertaken using MAGENTA63 as previously described15. Gene 
sets/pathways with FDR<5% either including the HLA region or excluding the HLA region were 
reported.  
Tissue specific enrichment of overlap of histone marks 
Two methods were used to test for enrichment of the 97 signals of association with lung function for 
H3K4me1 and H3K4me3 histone marks in up to 127 different tissue and cell types from the ENCODE 
and RoadMap projects39.  
First, enrichment was investigated using a hypergeometric test (as previously described39) using 
SNPs from the GWAS Catalog (hg19, downloaded 02/11/2015) as background. The GWAS Catalog 
was pruned within each contributing GWAS study to retain only SNPs that were at least 1Mb apart 
within that study resulting in 18,202 SNPs for further analysis. BEDtools was used to calculate 
overlap with precomputed “gapped peaks” for H3K4me1 and H3K4me3 histone marks and a 
hypergeometric test was used to test the significance of enrichment of the 97 lung function variants 
compared to the background of GWAS Catalog SNPs. Control for multiple testing was undertaken by 
picking 97 random variants from the pruned GWAS Catalog and repeating the enrichment 
computation. FDR was calculated from 10,000 randomizations and FDR=10% was used as a 
threshold. 
The second method used, GoShifter, calculates overlap enrichment against a null distribution 
generated by locally shifting annotations64. Linkage disequilibrium was calculated using the stage 1 
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population. Precomputed “narrow peaks” for H3K4me1 and H3K4me3 histone marks from the 
Roadmap project were used. Tissues/cell types with overlap enrichment P<0.05 are reported. 
Druggability 
We searched the ChEMBL database (v21, last update: 01/02/2016, downloaded on 11/02/16) to 
identify whether any of the implicated genes encoded proteins that were targets for approved 
drugs, or drug compounds in development. We additionally searched for genes predicted to interact 
(parameters: STRING score ≥0.90; maximum of 10 interactions per gene) with each of the high-
priority genes32. 
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